Gregory D. Vite

4.6k citations

64 papers · 2.8k indexed · h-index 28

Impact in

Oncology top 2%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
Organic Chemistry top 2%
- Synthetic Organic Chemistry Methods

Papers in

Organic Chemistry 30
- Synthetic Organic Chemistry Methods 9
- Oxidative Organic Chemistry Reactions 6
Oncology 27
- HER2/EGFR in Cancer Research 16
- Cancer Treatment and Pharmacology 13

Co-authors: R. M. Borzilleri Craig R. Fairchild Francis Y. F. Lee Robert A. Kramer Soong‐Hoon Kim Byron H. Long William C. Rose Bert Fraser‐Reid
Journals: Bioorganic & Medicinal Chemistry Letters (16 papers)The Journal of Organic Chemistry (8 papers)Organic Letters (5 papers)Cancer Research (4 papers)Journal of the American Chemical Society (3 papers)
Partner nations: United States Germany Japan

In The Last Decade

Gregory D. Vite

63 papers receiving 2.7k citations

Peers

Countries citing papers authored by Gregory D. Vite

Since Specialization

Citations

This map shows the geographic impact of Gregory D. Vite's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory D. Vite with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory D. Vite more than expected).

Fields of papers citing papers by Gregory D. Vite

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory D. Vite. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory D. Vite. The network helps show where Gregory D. Vite may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Gregory D. Vite, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gregory D. Vite Line = papers co-authored together Gregory D. Vite links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer Bioorganic & Medicinal Chemistry Letters ·Di Donato Giulia, Upender Velaparthi, Mark G. Saulnier, David B. Frennesson, Peiying Liu, Audris Huang, John S. Tokarski, Aberra Fura, Thomas Spires, John A. Newitt, Benoît Côté, Mary T. Obermeier, Paul A. Elzinga, Marco M. Gottardis, Lata Jayaraman, Gregory D. Vite, Aaron Balog	2022	7
2	Design, synthesis and biological evaluation of phenol-linked uncialamycin antibody-drug conjugates Bioorganic & Medicinal Chemistry Letters ·Yam B. Poudel, Chetana Rao, Srikanth Kotapati, Madhura Deshpande, M. Loick, Chin Pan, He Rong Yen, Naidu S. Chowdari, Lillian Liva Foltran, apoole, BO Jin-Jiang, M. Zainul Arifin, Pirama Nayagam Arunachalam, Shrikant Deshpande, Vangipuram S. Rangan, M. Carley, Arvind Mathur, Gregory D. Vite, Sanjeev Gangwar	2019	26
3	Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors Bioorganic & Medicinal Chemistry Letters ·David Williams, Jay A. Markwalder, Aaron Balog, Bin Chen, Libing Chen, B. M. Mikhova, Estéfany Melo Munari, Amy C. Hart, Sunil K. Mandal, Andrew Nation, Weifang Shan, Gregory D. Vite, Kelly L. Covello, John T. Hunt, Maria Jure–Kunkel, Steven P. Seitz	2018	15
4	Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy Bioorganic & Medicinal Chemistry Letters ·Naidu S. Chowdari, Chin Pan, Chetana Rao, David R. Langley, Prasanna Sivaprakasam, Vicente 1726-1788 grab. Galcerán y Alapont, Neil M. Cohen, Yichong Wang, Zhamol Shihnazarov, David Passmore, Vangipuram S. Rangan, Shrikant Deshpande, Pina M. Cardarelli, Gregory D. Vite, Sanjeev Gangwar	2018	25
5	Synergistic inhibition of Aβ production by combinations of γ-secretase modulators European Journal of Pharmacology ·Alan S. Robertson, Lawrence G. Iben, Cong Wei, Jere E. Meredith, Dieter M. Drexler, Martyn Banks, Gregory D. Vite, Richard E. Olson, Lorin A. Thompson, Charles F. Albright, Michael K. Ahlijanian, Jeremy H. Toyn	2017	3
6	Macrocyclic pyrrolobenzodiazepine dimers as antibody-drug conjugate payloads Bioorganic & Medicinal Chemistry Letters ·Beatrice Amuge, Yong Zhang, Erik M. Stang, Donna Wei, Andrew J. Tebben, Heidi L. Perez, Gretchen M. Schroeder, Chin Pan, Chetana Rao, R. M. Borzilleri, Gregory D. Vite, Sanjeev Gangwar	2017	5
7	Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors Bioorganic & Medicinal Chemistry Letters ·Jay A. Markwalder, Steven P. Seitz, Yuval Blat, Lisa Elkin, John T. Hunt, Jonathan G. Pabalan, Maria Jure–Kunkel, Gregory D. Vite, Kelly L. Covello	2016	23
8	Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers Experimental Cell Research ·Maodeji Peng, Patrizia Banfi, Fabio Gasparri, R. M. Borzilleri, Percy Carter, Lyndon A. M. Cornelius, Marco M. Gottardis, 허보윤, Claudio Mapelli, Joseph G. Naglich, Andrew J. Tebben, Gregory D. Vite, Wilma Pastori, Clara Albanese, Emiliana Corti, Dario Ballinari, Arturo Galvani	2014	27
9	Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families Clinical Cancer Research ·Tai W. Wong, Francis Y. Lee, Stuart L. Emanuel, Craig R. Fairchild, Joseph Fargnoli, Brian E. Fink, Ashvinikumar V. Gavai, حمید زارعی, Benjamin J. Henley, R. Tamil Selvi, John T. Hunt, Bala Krishnan, Daniel Kukral, Anne Lewin, Nariaki Oikawa, Derek Norris, Simone Oppenheimer, Gregory D. Vite, Chiang Yu	2011	18
10	Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid Bioorganic & Medicinal Chemistry Letters ·Iontcho R. Vlahov, Gregory D. Vite, Paul J. Kleindl, Yu Wang, Hari Krishna R. Santhapuram, Fei You, Stephen Howard, Soong‐Hoon Kim, Bai Feng, Christopher P. Leamon	2010	29
11	Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases Bioorganic & Medicinal Chemistry Letters ·Brian E. Fink, Derek Norris, Harold Mastalerz, Ping Chen, Bindu Goyal, Yufen Zhao, Soong‐Hoon Kim, Gregory D. Vite, Francis Y. Lee, Hongjian Zhang, Simone Oppenheimer, John S. Tokarski, Tai W. Wong, Ashvinikumar V. Gavai	2010	23
12	Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer Cancer Research ·Ricardo M. Attar, Maria Jure–Kunkel, Aaron Balog, Mary Ellen Cvijic, Keeli Rae Snow, Cheryl A. Rizzo, Liang Schweizer, Thomas Spires, J. Suso Platero, Mary T. Obermeier, Weifang Shan, Mark Salvati, William R. Foster, Joseph Dinchuk, Shen-Jue Chen, Gregory D. Vite, Robert A. Kramer, Marco M. Gottardis	2009	38
13	Synthesis and in vitro effects of BMS-753493, an epothilone-folate conjugate designed to selectively target FR expressing tumor cells Cancer Research ·Gregory D. Vite, Iontcho R. Vlahov, Steven Howard, Soong‐Hoon Kim, Paul J. Kleindl, Hari Krishna R. Santhapuram, Yu Wang, Mei-Li Wen, Christopher P. Leamon, Francis Lee	2008	2
14	Preclinical efficacy spectrum and pharmacokinetics of ixabepilone Cancer Chemotherapy and Pharmacology ·Francis Y. F. Lee, Richard Smykla, Kathy Johnston, Krista Menard, Kelly McGlinchey, Russell W. Peterson, Mollimichelle McClendon, Gregory D. Vite, Craig R. Fairchild, Robert A. Kramer	2008	83
15	Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists Bioorganic & Medicinal Chemistry Letters ·Mark Salvati, Aaron Balog, Weifang Shan, M. Carley, Zahraa Haguar, WANG Jiping, NielsonFlemming, Gregory D. Vite, Ricardo M. Attar, Maria Jure–Kunkel, Jieping Geng, Cheryl A. Rizzo, Marco M. Gottardis, Stanley R. Krystek, Jack Z. Gougoutas, Michael A. Galella, Mary T. Obermeier, Aberra Fura, Gamini Chandrasena	2008	20
16	Preclinical discovery of ixabepilone, a highly active antineoplastic agent Cancer Chemotherapy and Pharmacology ·Francis Y. F. Lee, R. M. Borzilleri, Craig R. Fairchild, Amrita V. Kamath, Richard Smykla, Robert A. Kramer, Gregory D. Vite	2008	88
17	Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases Bioorganic & Medicinal Chemistry Letters ·Harold Mastalerz, Ming Chang, Ashvinikumar V. Gavai, Walter L. Johnson, David R. Langley, Francis Y. Lee, Punit Marathe, Arvind Mathur, Simone Oppenheimer, H. Morton-Coval, John S. Tokarski, Gregory D. Vite, Dolatrai M. Vyas, Henry Ν. C. Wong, Tai W. Wong, Hongjian Zhang, Guifen Zhang	2007	24
18	Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics Molecular Cancer Therapeutics ·Kristen A. Kellar, Matthew V. Lorenzi, Ira Duncan, Dan You, Mei-Li Wen, Lauren A. Pace, Simone Oppenheimer, Brian E. Fink, Gregory D. Vite, Bruce R. Rowley, Chiang Yu, David K. Bol, Francis Y. Lee, Tai W. Wong	2006	5
19	New dual inhibitors of EGFR and HER2 protein tyrosine kinases Bioorganic & Medicinal Chemistry Letters ·Brian E. Fink, Gregory D. Vite, Harold Mastalerz, John F. Kadow, Soong‐Hoon Kim, Kenneth J. Leavitt, Mary Lou Nester, Lílian Vilela de Andrade Pinto, Toomas Mitt, Tai W. Wong, John T. Hunt, Dolatrai M. Vyas, John S. Tokarski	2005	37
20	Identification of novel functional inhibitors of 17β-hydroxysteroid dehydrogenase type III (17β-HSD3) The Prostate ·Thomas Spires, Brian E. Fink, Ellen K. Kick, Dan You, Cheryl A. Rizzo, Ivone M. Takenaka, R. Michael Lawrence, Zheming Ruan, Mark Salvati, Gregory D. Vite, Roberto Weinmann, Ricardo M. Attar, Marco M. Gottardis, Matthew V. Lorenzi	2005	22

About Gregory D. Vite

Gregory D. Vite is a scholar working on Organic Chemistry, Oncology, Biological Psychiatry, Toxicology and Molecular Biology, having authored 64 papers that have together received 2.8k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (16 papers), Cancer Treatment and Pharmacology (13 papers), Synthetic Organic Chemistry Methods (9 papers), Chemical Synthesis and Analysis (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Oxidative Organic Chemistry Reactions (6 papers), Estrogen and related hormone effects (6 papers) and Hormonal and reproductive studies (5 papers). The work is most often cited by research in Oncology (1.1k citations), Organic Chemistry (1.0k citations), Toxicology (89 citations), Molecular Biology (1.3k citations) and Pharmacology (282 citations). Gregory D. Vite has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include R. M. Borzilleri, Craig R. Fairchild, Francis Y. F. Lee, Robert A. Kramer, Soong‐Hoon Kim, Byron H. Long, William C. Rose, Bert Fraser‐Reid, Sanjeev Gangwar and Shrikant Deshpande. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, The Journal of Organic Chemistry, Organic Letters, Cancer Research and Journal of the American Chemical Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact